Infusion of Pituitary Adenylate Cyclase-Activating Polypeptide-38 in Patients with Rosacea Induces Flushing and Facial Edema that Can Be Attenuated by Sumatriptan

What Was Tested

Researchers studied PACAP in the context of rosacea in this randomized controlled trial publication.

The pathogenesis of rosacea is incompletely understood.

Signaling neuropeptides, including PACAP, a regulator of vasodilation and edema, are upregulated in rosacea skin.

Who Took Part

The study group was 35 patients.

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got PACAP and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on PACAP, so expectations could not easily colour the readings.

Some patients received a placebo instead of PACAP, giving a reference point.

In the crossover set-up each of the patients took both PACAP and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Edema, Face, Flushing, Pituitary Adenylate Cyclase-Activating Polypeptide, Rosacea and Sumatriptan.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of PACAP in 35 patients in people with rosacea.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (The Journal of investigative dermatology), a journal based in United States.

More context: the PACAP compound page, Rosacea research.